BiotechTube
Stada

Stada

Bad Vilbel, Germany
stada.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

STADA is a major, revenue-generating European pharmaceutical player with a diversified three-pillar strategy encompassing generics, consumer healthcare, and specialty pharmaceuticals. With adjusted revenues of €4.3 billion in FY2025 and a presence in over 100 countries, it leverages a portfolio of trusted brands and a deep generics pipeline to drive growth. The company is well-established, employing nearly 12,000 people, and focuses on operational execution and portfolio expansion rather than novel drug discovery.

Various (Generics)Consumer HealthBiosimilars

Technology Platform

Integrated platform for the development, manufacturing, and commercialization of generic drugs, biosimilars, and consumer healthcare products, focusing on process engineering and regulatory strategies for post-patent markets.

Opportunities

The global push for healthcare cost containment drives sustained demand for affordable generics and biosimilars.
STADA can leverage its strong European footprint and growing presence in emerging markets to expand its portfolio of complex generics and biosimilars, which command better margins.
Acquisitions of complementary brands or product portfolios offer a clear path to accelerated growth.

Risk Factors

The generics market faces severe pricing pressure from healthcare payers and intense competition, threatening profitability.
The biosimilars segment, while high-growth, involves significant development cost, regulatory complexity, and legal challenges from originator companies.
Dependency on private equity ownership introduces financial leverage risk and potential for strategic shifts focused on shorter-term value realization.

Competitive Landscape

STADA competes in the generics and consumer health space against large global players like Teva, Sandoz (Novartis), Viatris, and Perrigo, as well as numerous regional competitors. In biosimilars, it faces competition from both dedicated biotech firms (e.g., Celltrion) and the generics divisions of large pharma. Its competitive edge lies in its strong regional commercial networks, portfolio breadth, and focus on complex product forms.

More companies in Biologics / Biosimilars →More companies in Germany →